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Abstract
Heterocyclic thiosemicarbazones, thioureas and their copper, nickel, and cobalt complexes were shown to
be potent hypolipidemic agents in male Sprague Dawley rats at 8 mg/kg/day, orally. These agents lowered
the activity of rat hepatic rate limiting enzymes for the synthesis of cholesterol and triglycerides. The effects
of these agnets on cytoplasmic ATP-dependent citrate lyase, acetyl CoA synthetase and HMG-CoA
reductase activities were reduced by a magnitude to explain the reduction of serum cholesterol levels
afforded by the compounds. The reduction of acetyl CoA carboxylase, sn-glycerol-3-phosphate synthetase
and phosphotidylate phosphohydrolase activities caused by the derivatives is of sufficient magnitude to
explain the observed reduction in serum triglycerides after administration ofthe agents.
Introduction
Metal complexes containing copper, iron, cobalt, chromium, calcium and sodium of amine-carboxyboranes
have previously been shown to have potent hypolipidemic activity in rodents at the low doses of 2.5 to 8
mg/kg lowering both serum cholesterol and serum triglyceride levels [1-3]. These agents modulated rat
lipoproteins in a manner so that LDL-cholesterol levels were reduced whereas HDL-cholesterol levels were
elevated [4], which should lead to an enhanced clearance of cholesterol from the body. These complexes
suppressed LDL-binding to tissue high affinity receptor thus reducing cholesterol uptake into peripheral
tissue. Yet the complexes accelerated HDL-aff’mity binding to hepatic receptor so that serum cholesterol
could be taken up and processed to bile salts and excreted via the biliary system. These metal complexes of
amine carboxyboranes also demonstrated antineoplastic/cytotoxicity and antiinflammatory activity [5,6].
The metal complexes of thiosemicarbazones have also been shown to have antineoplastic and
antiinflammatory activity [7-9]. The present study involved an investigation of their potential as
hypolipidemic agents in rodent.
Methods
Source of Compounds
All of the derivatives [Fig 1] have been synthesized and reported in the literature previously [7].
Hypolipidemic in vivo screen.
Sprague Dawley male rats [-400g] were administered drugs prepared in 1% carboxymethylcellulose [CMC]
by homogenization at 8 mg/kg/day orally for 16 days. On days 9 and 16 the rats were bled from the tail
vein collecxted into capillary tubes which were centrifuged at 3000 x g for 3 rain. Total cholesterol was
determined on the serum by the Libermann-Burchard method [10] determined at 620 nm. Serum
triglycerides were determined on day 16 using a commercial kit from Sigma Chemical, Co. which was read
at 580 nm. Clofibrate at 150 mg/kg/day, orally, gemfibrozil at 90 mg/kg/day, orally and lovastatin at 8
mg/kg/day, orally were determined at their standard therapeutic dose.
Rat Hepatic Enzyme Studies in vitro
Enzyme assays were performed on Sprague Dawley male rats [-450g] livers homogenized [10%] in 0.025
M sucrose + 0.001 M EDTA, pH 7.2. Literature methods [11] were used to examine the effects of the
compounds at 25, 50 and 100 laM over 60 min. ATP dependent citrate lyase [12], acetyl CoA synthetase
13], HMG-CoA reductase 14,15], acyl CoA cholesterol acyl transferase 16], cholesterol-Tc-hydroxylase
[17], acetyl CoA carboxylase [18], sn-glycerol-3-phosphate acyl transferase 19], phospha-
tidylate phosphohydrolase[20] and hepatic lipoprotein lipase [21].
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Statistic Analysis
Data displayed in the tables are the means _+ standard deviations of the mean expressed as percentage of the
control. N is the number of samples or animals per group. The Student’s "t"-test was used to determine
the probable level of significance (p) between test samples and control samples.
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Fig. 1" Structures of Thiosemicarbazones and Their Metal Complexes
Results
All of the thiosemicarbazones demonstrated significant hypolipidemic activity in male Sprague Dawley rats
at 8 mg/kg/day orally reducing both serum cholesterol and serum triglycerides by day 16 [Table 1]. These
effects were superior to the standards clofibrate at 150 mg/kg/day, gemfibrozil at 90 mg/kg/day and
lovastatin at 8 mg/kg/day. On day 16 compounds 2, 6, G and 8 caused greater than 40% reduction of
serum cholesterol levels while compounds 3, 4, 5, 9 and 10 afforded greater than 32% reduction.
Compounds I and 4 reduced serum triglycerides greater than 40% atter 16 days and compounds 2, 3, 6, 8
and 10 caused at least 35% reduction of serum triglycerides.
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Table Hypolipidemic Activity of Compounds 1-10 on Sprague Dawley Male Rats at 8 mg/kg/day
Orally’
Compound
2
3
4
5
6
7
8
9
10
Clofibrate @ 150 mg/kg
Gemfibrozil @ 90 mg/kg
Lovastatin @ 8 mg/kg
Control 1% CMC
Serum Cholesterol
Da] 9
81+5
62+4*
93+5
78+6*
71+5"
60+4*
52+4*
60+3*
82+4
82+/-5
88+/-7
91+/-5
85+/-4
100+/-5
Serum Triglycerides
Da 16 Day 9
71+/-3’ 76+/-3*
59+/-4* 78+/-4*
64+/-5* 72+/-2*
61+/-5" 69+/-3*
66+/-6* 82+/-5
55+/-4* 81+/-3
51+/-2" 84+/-5
57+/-5* 73+/-4*
67+/-3* 79+/-2*
62+/-4* 82+/-4
86+/-2 83+/-6
82+/-7 78+/-6*
78+/-5* 91+/-5
100+/-6 100+/-7
a 73 mg/dl; b 75 mg/dl; c 111 mg/dl; d 112 mg/dl
Da16
56+/-4*
64+/-4*
63+/-5*
59+/-3*
75+/-3*
61+/-5
72+/-5*
65+/-4*
75+/-4*
62+/-3*
74+/-7*
62+/-5*
86+/-7
100+/-6
The activities of the regulatory enzymes involved in vitro hepatic de novo cholesterol and triglyceride
syntheses and metabolism were significantly affected by the thiosemicarbazones and their metal complexes
after 60 min incubation [Table 2-4]. Acetyl CoA synthetase activity was suppressed in a concentration
manner causing greater than 50% reduction at 100 tM. The inhibition of ATP-dependent citrate lyase
activity followed a similar pattern of inhibition by the agents but the magnitude of reduction was a little
less than with acetyl CoA synthetase activity. The activity of the regulatory enzyme of cholesterol
synthesis HMG-CoA reductase was reduced in a concentration dependent manner so that greater than 50%
inhibition was achieved by compounds 3, 4, 6, 7, 8, 9 and 10. Compound 1 had the least effects on HMG-
CoA reductase activity after hour and also had the least ability to lower serum cholesterol levels in vivo.
The effects of the thiosemicarbazones on cholesterol-7c-hydroxylase activity were erratic, i.e compounds 4,
9 and 10 had no effect or less than 20% reduction, compounds 1, 2, 3, 6 and 8 caused moderate reductions
in activity of 24% to 41% and compound 7 afforded 62% reduction at 100 tM. Acyl-CoA cholesterol
acyl transferase activity was reduced only moderately by compounds 1, 7 and 8 by approximately 32%.
Acetyl CoA carboxylase activity was also affected in an erratic manner by the compounds. Compounds 1,5,
6 and 7 resulted in 44% to 75% suppression after 60 min at 100 tM. Compounds 4, 9 and 10 had
marginal effects and compounds 3 and 8 had no effects on the activity, sn-Glycerol-3-phosphate acyl
transferase activity was inhibited 48% to 70% by compounds 1, 3, 4, 7, 8 and 10 and 25% to 36% by
compounds 5 and 6 but compound 9 had no effect. Phosphatidylate phosphohydrolase activity was
markedly reduced greater than 70% at 100 tM with the exception of compound 9 which only caused 57%
reduction. Hepatic lipoprotein lipase activity was essentially unaffected by compounds 3, 5, 7, 8 and 9,
and was moderately reduced by compounds 4,6 and 10. Compounds 1 and 2 caused reduction of hepatic
lipoprotein lipase activity of45% to 59% after 60 min incubation
Discussion
The observed reduction in the activities of the hepatic regulatory enzymes caused by the thiosemicarbazones
and their metal complexes are of a magnitude to account for the reductions of serum cholesterol and
triglyceride levels after 16 days in vivo. The reduction of acetyl CoA synthetase
and ATP dependent citrate lyase activities not only would reduce the synthesis of cholesterol in the
cytoplasm of the cell but would also lower the levels of fatty acids and neutral lipids since acetyl-CoA is
the common starting intermediate for all of the synthestic pathoways for these lipids. The fact that there was
a positive correlation between the ability of the compounds to reduce the activity ofHMG-CoA reductase
and its ability to lower serum cholesterol levels indicates that this may be a key target of the
thiosemicarbazones and their metal complexes.
Reduction of cholesterol-7c-hydroxylase activity by a few compounds would lead to less cholesterol being
converted to bile acids for biliary excretion. For the few compounds that inhibited acyl-CoA cholesterol
acyl transferase activity less cholesterol esters would be stored in the liver. If the analogous reaction
occurred in aorta foam cells then reducing cholesterol esters would reduce the size ofthe plaque.
Table 2: The Effects of Thiosemicarbazones on Sprague Dawley Liver Enzyme Activities
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Assa,
(N=6)
Acetyl CoA S,nthetase 100+5
ATP dependent Citrate L,ase 100+4
HMG-CoA reductase 100+6
Cholesterol-7o h,dr0x’lasea 100+7
AcyI-CoA Cholesterol Acl Transferase 100+5
Actyl CoA carbox,lase 100+4
sn-Gl,cer01-3-Phosphate
g Acl Transferase" 100+5
Phosphatid,late Phosph0h’drolase’ i00+6
Hepatic Lipoprotein Lipasd 100+5
Control Compound 1 Compound 2
25M 50tM. 106].tM 25M 50M 1001aM"
69+/-5* 47+4* 20+2* 99+/-6 63+3* 47+4*
65+/-4* 51+/-4" 38+/-3* ’48+/-4 36+/-4* 30+/-3*
87+/-5 87+/-6 80+/-4* 80+/-4* 61+/-4" 57+/-5*
104+/-6 89+/-5 79+/-5* 96+/-6 90+/-5 75+/-5*
107+/-6 84+/-5 65+/-5 116+/-6 82+/-6 80+/-4"
61+/-5" 51+/-4" 37+/-4* 68+/-4* 63+/-4* 56+/-3*
86+/-5 64+/-5* 40+/-3* 61+/-3" 57+/-5* 52+/-4*
79+/-4* 37+/-4* 173’ 85+/-6 39+/-3* 19+/-2’
67+/-3* 61+/-4" 55+/-4*’ 51+/-4" 45+/-4* 41+/-3"
Assay Control Compound 7
(N 6) 25tM 50tM
Acet),l C0A S,nthetase 100+/-5 128+/-8 52+/-5*
ATP dependent Citrate L,ase 100+/-4 52+/-5* 39+/-5* 35+/-4*
HMG-CoA reductase 100+/-6 57+/-4* 53+/-5* 48+/-3*
Cholesteroi-7c h2cdroxclase 100+/-7 74+/-3* 52+/-4* 38+4*
AcyI-CoA Cholesterol.Ac’l T.ransferase 100+/-5 99+/-7’ 82+/-5 67+/-4*
Acetl CoA carbox,lase 100+4 54+5* 44+/-4* 40+2*
sn-Glcerol-3-Phosphate Ac,l Transferase. 100+/-5 i08+/-6 80+/-5* 30+/-3*
Phosphatidlate Phosphohydrolase 100+/-6 58+/-5* 28+/-3* 19+/-2"
Compound 9
100[aM 25].tM 50}.tM 100M
38+/-4* 110+/-7 50+/-5* 28+/-4*
97+/-6 94+/-5 67+/-4*
48+/-4* 43+/-3* 43+/-3*
132+/-6’ 115+/-5 97+/-6
146+/-8" 123-6’ 97+/-5
87+/-5’ 72+/-4’ 63+/-3’
131+/-5’ 100+/-6 97+/-5
129+/-6’ 60+/-5* 43+/-4*
Hepatic Lipoprotein Lipase 100+/-5 112+/-5 84+/-5 83+/-4 98+/-6 95+/-5 89+/-6
a 10.1 mg acetyl CoA formed/g wet tissue; b 9.2 mg citrate hydrolyzed/g wet tissue; c 103,020
dpm/g wet tissue; d 289, 450 dpm/g wet tissue; e 86,640 dpm/g wet tissue; f= 43021 dpm/g wet
tissue; g 87, 620 dpm/g wet tissue; h 11 j.tg Pi released/g wet tissue;i 234,675 dpm/g wet tissue.
Table 3
Activities
Assay
(N 6).
Acetyl CoA Synthetase"
ATP dependent Citrate.L,ase
HMG-CoA reductase
Cholesterol-7a h,drox’lase
Ac,I-COA Cholesterol Ac,I Yransferase
Acetl CoA carbox,lase’
sn-Gl,cerol-3-Phosphateg .AcI Transferase"
phosphatid,late Phosphoh,drolase’
Hepatic Lipoprotein Lipasd
The Effects of Nickel Complexes of Thiosemicarbazones On Sprague Dawley Liver Enzyme
Control
251aM
100+/-5 46+/-4" 31+/-4"
100+4 "69+/-’5’ 49+3’
100+6 65+/-4*
100+/-7 93+/-5
100+/-5 116+/-6
100+/-4 115+/-6
100+/-5 56+/-4"
100+/-6 70+/-3 *
100+/-5 129+/-7
Compound 3 Compound 4
50laM 100M 25M 50M 1001aM
19+/-3’ 98+/-5 48+/-4* 10+2’
39+/-2* 80+/-4* 58+/-3* 47+/-3*
53-3" 42+/-4" 76+/-4" 48+/-3" 48+/-4"
76+/-3* 62+/-3* "112+/-6’ 97+/-5 84+/-4
88+/-5 77+/-5 88+/-5 87+/-5 82+/-4
96+/-5 87+/-6 102+/-5 92+/-6 72+/-4"
54+/-3* 51+/-3" 67+/-3* 60+/-6 46+/-3*
29+/-3" 23+/-3 100+/-4 46+/-4’ 21+3"
90+/-6 90+/-6 104+5 97+6 73+5"
Assay
(N 6)
Acet),l CoA S),nthetase
ATP dependent Citrate Lyase
HMG-CoA reductase
Cholesterol-7tx h]cdroxylase
Acyl-CoA Cholesterol Ac,l Transferase
Acetyl CoA carboxylase
sn-Glycerol-3-Phosphate Acyl Transferase
Phosphatidylate Phosphohydrolase
Hepatic Lipoprotein Lipase
Control Compound 5 Compound 6
251.tM 50l.tM 100}.tM 251.tM 50].tM 1001.tM_-
100+/-5 121+/-5 67+/-4* 42+/-4* 72+/-4* 48+4* 32+/-3*
100+/-4 93+/-6 65+/-5* 53-5’ -80+6 54+3* 41+/-2"
100+6 67+/-5* 57+/-5* 56+/-4*’66+4* 42+/-4* 40+/-3*
100+7 107+/-6 88+/-6 76+/-5* 89+/-6 81+/-4 59+4*
100+/-5 ’89+/-7 87+/-6 83+/-5 122+/-5 99+6 86+5
100+/-4 45+/-4* 35+/-3* 25+/-4 49+/-4* 42+/-4* 42+/-3*_
100+/-5 124+5 107+/-6 75+/-4’ 116+6 66+5" 64+/-3"
100+/-6 44+3* 25+/-4* 19+/-3’ ’48+/-3* 26+3* 13+/-2"
100+/-5 149+7’ 140+/-8’ 954-6 894 83+5 73+/-4*
The reduction of acetyl CoA carboxylase activity by the thiosemicarbazones and their metal complexes
would lead to less synthesis of fatty acids and the suppression of sn-glycerol-3-phosphate acyl transferase
activity would lead to less neutral lipid synthesis. The ability of the compounds to lower phosphatidylate
phosphohydrolase activity would block the removal of the phosphorus moiety from phospholipids so that
triglyceride could be formed. This again appears to be major target of the agents in lowering serum
triglyceride levels.
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Interestingly there did not appear to be any differences in the effects of thiosemicarbazones compared to
their metal complexes on either the serum lipid levels or the enzyme activities. Nor did any one type of
metal complex appear to be better in reducing these parameters compared to another. The amine
carboxyboranes and their metal complexes also demonstrated a pattern of having multiple target enzymes
within de novo lipid synthesis [1-3]. These derivatives had more effect on acyl-CoA cholesterol acyl
transferase activity than the thiosemicarbazones and its metal complexes while the thiosemicarbazones and
their metal complexes had more effects on HMG-CoA reductase activity than the amine carboxyboranes and
their metal complexes. Similar effects were observed on the other enzyme activities examined by both
groups ofcompounds as well as the magnitude of serum cholesterol and triglyceride reduction in rodents.
Table 4 The Effects of Cobalt Complexes of Thiosemicarbazones On Sprague Dawley Liver Enzyme
Activities
Assay Control Compound 8 Compound 10
(N 6) 25}.tM 501aM 100}.tM 25}.tM 501aM 100tM
AcetylCoA S’nthetase 100+5 83+5* 57+/-4* 36+3* 53+4* 33+3* 20+3"..
ATP dependent Citrate L’ase 100+4 63+4* 39+3 35+3* 111+5 68+4* 43+3*
HMG-CoAreductase 100+6 54+5* 48+3* 32+4* 56+5* 46+/-4* 45+/-4*
Cholesterol-7 hcdrox’lase 100+7 79+/-6* 71+/-4" 57+/-4* i’i8+/-6 108+/-5 93+/-5
Ac2cI-CoA Cholesterol Ac21Transferase 100+/-5 101+/-5 74+/-5* 61+/-4" 110+5 84+/-5 77+/-3*
Acetl CoA carbox,lase 100+/-4 70+/-4* 96+/-5 87+6 102+/-5 92+/-6 72+/-4*
sn-Gl2ccerol-3-Phosphate
g Ac"’i’ Transferase" 100+/-5 56+/-4* 54+/-3* 51+/-3" 67+/-3* 60+/-4* 46+/-3*.
Phosphatidylate Phosphoh,drolase’ 100-6 70+/-5* 29+/-3* 23+/-3* 100+/-4 46+/-4* 21+/-3"
Hepatic Lipoprotein Lipase 100+/-5 129+/-7" 90+/-5 90+/-6 104+/-5 97+/-6 73+/-5 +’’’
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